profit from every $100 of sales.
$0$100
Klotho Neurosciences
We have no price for Klotho Neurosciences since 11 March 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.09-13.13% today
-58.5% since Oct 10, 25
1-year low $0.071-year high $0.21
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Klotho Neurosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Klotho Neurosciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Klotho Neurosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 2.2×
- –
- –
- –
- -93.6%
- -168.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -75.1%
- -141.8%
- -137.6%
- -110.0%
- -75.1%
- –
Growth
- –
- –
- −107.8%
- –
- +48.2%
Financial health
- -1.0×
- 0.00
- 0.0%
- -2.0×
- 95.01
- 95.01
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 952
Bottom 20%of 884
Bottom 1%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
18No pass
Benjamin Graham
42No pass
Philip Fisher
30No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
18No pass
Questions about Klotho Neurosciences
Is Klotho Neurosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Klotho Neurosciences AI analysis
What does Klotho Neurosciences do?
Klotho Neurosciences, Inc. is a biopharmaceutical company focused on developing medical treatments for a variety of severe illnesses, including cancer, heart disease, and conditions affecting the nervous system. It is in Biotechnology.
Does Klotho Neurosciences pay a dividend?
No. Klotho Neurosciences does not pay a dividend at the moment.
Is Klotho Neurosciences stock halal?
Yes. Klotho Neurosciences passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
Who are Klotho Neurosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Klotho Neurosciences's.
Prices: daily closes to Mar 11, 2026. Fundamentals: company reports via invest-like data.